MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jnma.2025.11.010

Медицинская библиотека · Journal of the National Medical Association · 2025

Incidence and demographic patterns of neutropenia in clozapine-treated patients with schizophrenia: A 20-year retrospective cohort study.

Ahmed Sumaiya, Beyene Elizabeth, Bisrat Mekdem, Falegan Toyosi, Hemphill Aaron, Mack Aaron, Elkomi Rawan, Zinabu Samrawit, Michael Miriam

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS), yet its use is often limited by the risk of hematologic adverse effects, particularly neutropenia and agranulocytosis. These risks have led to strict monitoring requirements, contributing to underutilization despite strong evidence of clinical benefit. Real-world data on neutropenia incidence across demographic groups can inform risk-stratified monitoring and reduce unnecessary treatment interruptions.

OBJECTIVE

To determine the incidence, prevalence, and demographic distribution of neutropenia in clozapine-treated patients with schizophrenia over a 20-year period using a large multicenter dataset.

METHODS

A retrospective cohort study was conducted using electronic health records from the TriNetX Research Network (2005-2025). Adult patients with schizophrenia receiving clozapine were identified. Neutropenia was defined by ICD-10-CM codes D70, D70.8, and D70.2. Incidence proportion, prevalence, and incidence rate (cases per million person-days) were calculated and stratified by age, sex, race, and ethnicity.

RESULTS

Among clozapine-treated patients, the overall incidence proportion of neutropenia was 3.17 %, with an incidence rate of 8.6 cases per million person-days. The highest incidence occurred in patients aged ≥70 years, peaking at 76.9 % in the 75-79 age group. Rates were modest (2-4 %) among adults aged 20-64. Higher incidence was observed among Black or African American (4.6 %) and American Indian/Alaska Native patients (10.1 %), likely reflecting benign ethnic neutropenia.

CONCLUSIONS

Neutropenia is uncommon in most adult clozapine-treated patients, supporting the relative hematologic safety of broader use in TRS. Findings suggest that monitoring protocols could be revised to reflect actual risk, potentially improving clozapine access and reducing treatment disparities.

Для цитирования: Ahmed Sumaiya, Beyene Elizabeth, Bisrat Mekdem, Falegan Toyosi, Hemphill Aaron, Mack Aaron, Elkomi Rawan, Zinabu Samrawit, Michael Miriam. Incidence and demographic patterns of neutropenia in clozapine-treated patients with schizophrenia: A 20-year retrospective cohort study.. Journal of the National Medical Association. 2025. DOI: 10.1016/j.jnma.2025.11.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.